4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 101 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $86,777,991 | -10.9% | 4,134,254 | +35.2% | 0.02% | -11.8% |
| Q1 2024 | $97,423,069 | +489.0% | 3,057,849 | +274.6% | 0.02% | +466.7% |
| Q4 2023 | $16,539,109 | +720.9% | 816,343 | +415.8% | 0.00% | – |
| Q3 2023 | $2,014,828 | -42.6% | 158,274 | -18.5% | 0.00% | -100.0% |
| Q2 2023 | $3,510,369 | +3.2% | 194,265 | -1.8% | 0.00% | 0.0% |
| Q1 2023 | $3,400,216 | +29.4% | 197,802 | +67.1% | 0.00% | 0.0% |
| Q4 2022 | $2,628,420 | +311324.2% | 118,344 | +12.6% | 0.00% | – |
| Q3 2022 | $844 | -9.4% | 105,070 | -21.3% | 0.00% | – |
| Q2 2022 | $932 | -99.9% | 133,563 | +77.0% | 0.00% | – |
| Q1 2022 | $1,141,000 | +55.2% | 75,458 | +125.3% | 0.00% | – |
| Q4 2021 | $735,000 | +181.6% | 33,495 | +245.8% | 0.00% | – |
| Q3 2021 | $261,000 | -51.8% | 9,686 | -22.4% | 0.00% | – |
| Q1 2021 | $542,000 | -82.6% | 12,486 | -83.3% | 0.00% | -100.0% |
| Q4 2020 | $3,108,000 | – | 74,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |